Graves’ Orbitopathy Models: Valuable Tools for Exploring Pathogenesis and Treatment

Abstract

Graves’ orbitopathy (GO) is the most common extrathyroidal complication of Graves’ disease (GD) and severely affects quality of life. However, its pathogenesis is still poorly understood, and therapeutic options are limited. Animal models are important tools for preclinical research. The animals in some previous models only exhibited symptoms of hyperthyroidism without ocular lesions. With the improvements achieved in modeling methods, some progressive animal models have been established. Immunization of mice with A subunit of the human thyroid stimulating hormone receptor (TSHR) by either adenovirus or plasmid (with electroporation) is widely used and convincing. These models are successful to identify that the gut microbiota influences the occurrence and severity of GD and GO, and sex-related risk factors may be key contributors to the female bias in the occurrence of GO rather than sex itself. Some data provide insight that macrophages and CD8+ T cells may play an important pathogenic role in the early stage of GO. Our team also replicated the time window from GD onset to GO onset and identified a group of CD4+ cytotoxic T cells. In therapeutic exploration, TSHR derived peptides, fingolimod, and rapamycin offer new potential options. Further clinical trials are needed to investigate these drugs. With the increasing use of these animal models and more in-depth studies of the new findings, scientists will gain a clearer understanding of the pathogenesis of GO and identify more treatments for patients.

Key words

Graves’ orbitopathy - animal model - plasmid - adenovirus - TSHR A subunit

Publikationsverlauf

Eingereicht: 20. Juni 2023

Angenommen nach Revision: 21. August 2023

Artikel online veröffentlicht:
30. Oktober 2023

• References

• 1 Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves' disease: a 2014 update. J Endocrinol Invest 2014; 37: 691-700
• 2 Bartalena L, Baldeschi L, Boboridis K. et al. The 2016 European thyroid association/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J 2016; 5: 9-26
• 3 Fang S, Lu Y, Huang Y. et al. Mechanisms that underly T cell immunity in Graves' orbitopathy. Front Endocrinol 2021; 12: 648732
• 4 Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 362: 726-738
• 5 Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994; 92: 477-588
• 6 Eckstein AK, Losch C, Glowacka D. et al. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol 2009; 93: 1052-1056
• 7 Farid M, Roch-Levecq AC, Levi L. et al. Psychological disturbance in Graves ophthalmopathy. Arch Ophthalmol 2005; 123: 491-496
• 8 Abraham-Nordling M, Wallin G, Traisk F. et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol 2010; 163: 651-657
• 9 Taylor PN, Zhang L, Lee RWJ. et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 2020; 16: 104-116
• 10 Kahaly GJ, Petrak F, Hardt J. et al. Psychosocial morbidity of Graves' orbitopathy. Clin Endocrinol (Oxf) 2005; 63: 395-402
• 11 Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol 2017; 5: 134-142
• 12 Genere N, Stan MN. Current and emerging treatment strategies for Graves' orbitopathy. Drugs 2019; 79: 109-124
• 13 Smith TJ, Kahaly GJ, Ezra DG. et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 2017; 376: 1748-1761
• 14 Douglas RS, Kahaly GJ, Patel A. et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020; 382: 341-352
• 15 Winn BJ, Kersten RC. Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies. Ophthalmology 2021; 128: 1627-1651
• 16 Salvi M, Vannucchi G, Curro N. et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015; 100: 422-431
• 17 Stan MN, Garrity JA, Carranza Leon BG. et al. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab 2015; 100: 432-441
• 18 Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR. et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 2018; 195: 181-190
• 19 Rajendram R, Taylor PN, Wilson VJ. et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 x 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 299-309
• 20 Khong JJ, McNab AA, Ebeling PR. et al. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol 2016; 100: 142-150
• 21 Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. Exp Eye Res 2016; 142: 83-91
• 22 Weightman DR, Perros P, Sherif IH. et al. Autoantibodies to IGF-1 binding-sites in thyroid-associated ophthalmopathy. Autoimmunity 1993; 16: 251-257
• 23 Feliciello A, Porcellini A, Ciullo I. et al. Expression of thyrotropin-receptor messenger-RNA in healthy and Graves-disease retro-orbital tissue. Lancet 1993; 342: 337-338
• 24 Pritchard J, Han R, Horst N. et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003; 170: 6348-6354
• 25 Douglas RS, Naik V, Hwang CJ. et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008; 181: 5768-5774
• 26 Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol 2015; 11: 171-181
• 27 Pappa A, Lawson JM, Calder V. et al. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol 2000; 84: 517-522
• 28 Xia N, Zhou S, Liang Y. et al. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy. Int J Mol Med 2006; 17: 911-916
• 29 Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology 2006; 147: 13-19
• 30 Huang Y, Fang S, Li D. et al. The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond) 2019; 33: 176-182
• 31 Fang S, Huang Y, Wang S. et al. IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab 2016; 101: 2955-2965
• 32 Fang S, Huang Y, Zhong S. et al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in Graves orbitopathy. J Clin Endocrinol Metab 2017; 102: 4273-4283
• 33 Wang Y, Chen Z, Wang T. et al. A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves' orbitopathy. Cell Mol Immunol 2021; 18: 735-745
• 34 Eckstein AK, Plicht M, Lax H. et al. Thyrotropin receptor autoantibodies are independent risk factors for graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91: 3464-3470
• 35 Stohr M, Oeverhaus M, Lytton SD. et al. Predicting the relapse of hyperthyroidism in treated Graves' disease with orbitopathy by serial measurements of TSH-receptor autoantibodies. Horm Metab Res 2021; 53: 235-244
• 36 Stohr M, Oeverhaus M, Lytton SD. et al. Predicting the course of Graves' orbitopathy using serially measured TSH-receptor autoantibodies by automated binding immunoassays and the functional bioassay. Horm Metab Res 2021; 53: 435-443
• 37 Ludgate M, Baker G. Inducing Graves' ophthalmopathy. J Endocrinol Invest 2004; 27: 211-215
• 38 Smelser GK. Experimental production of exophthalmos resembling that found in Graves disease. Proc Soc Exp Biol Med 1936; 35: 128-130
• 39 Many MC, Costagliola S, Detrait M. et al. Development of an animal model of autoimmune thyroid eye disease. J Immunol 1999; 162: 4966-4974
• 40 Baker G, Mazziotti G, von Ruhland C. et al. Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy. Endocrinology 2005; 146: 835-844
• 41 Costagliola S, Many MC, Denef JF. et al. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J Clin Invest 2000; 105: 803-811
• 42 Costagliola S, Rodien P, Many MC. et al. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J Immunol 1998; 160: 1458-1465
• 43 Johnson KTM, Wiesweg B, Schott M. et al. Examination of orbital tissues in murine models of Graves' disease reveals expression of UCP-1 and the TSHR in retrobulbar adipose tissues. Horm Metab Res 2013; 45: 401-407
• 44 Loosfelt H, Pichon C, Jolivet A. et al. Two-subunit structure of the human thyrotropin receptor. Proc Natl Acad Sci U S A 1992; 89: 3765-3769
• 45 Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med 1997; 337: 1675-1681
• 46 Chen CR, Hubbard PA, Salazar LM. et al. Crystal structure of a TSH receptor monoclonal antibody: insight into Graves' disease pathogenesis. Mol Endocrinol 2015; 29: 99-107
• 47 Chen CR, Pichurin P, Nagayama Y. et al. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003; 111: 1897-1904
• 48 Kaneda T, Honda A, Hakozaki A. et al. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice. Endocrinology 2007; 148: 2335-2344
• 49 Zhao SX, Tsui S, Cheung A. et al. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol 2011; 210: 369-377
• 50 Moshkelgosha S, So PW, Deasy N. et al. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 2013; 154: 3008-3015
• 51 Berchner-Pfannschmidt U, Moshkelgosha S, Diaz-Cano S. et al. Comparative assessment of female mouse model of Graves' orbitopathy under different environments, accompanied by proinflammatory cytokine and T-cell responses to thyrotropin hormone receptor antigen. Endocrinology 2016; 157: 1673-1682
• 52 Masetti G, Moshkelgosha S, Kohling HL. et al. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease. Microbiome 2018; 6: 97
• 53 Moshkelgosha S, Verhasselt HL, Masetti G. et al. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease. Microbiome 2021; 9: 45
• 54 Dagdelen S, Kong YC, Banga JP. Toward better models of hyperthyroid Graves' disease. Endocrinol Metab Clin North Am 2009; 38: 343-354 viii
• 55 Nagayama Y, Kita-Furuyama M, Ando T. et al. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002; 168: 2789-2794
• 56 Chen CR, Pichurin P, Chazenbalk GD. et al. Low-dose immunization with adenovirus expressing the thyroid-stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease. Endocrinology 2004; 145: 228-233
• 57 McLachlan SM, Aliesky HA, Chen CR. et al. Role of self-tolerance and chronic stimulation in the long-term persistence of adenovirus-induced thyrotropin receptor antibodies in wild-type and transgenic mice. Thyroid 2012; 22: 931-937
• 58 Holthoff HP, Goebel S, Li Z. et al. Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves' disease, tachycardia, and cardiac hypertrophy. Endocrinology 2015; 156: 1577-1589
• 59 Jabbar A, Pingitore A, Pearce SH. et al. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14: 39-55
• 60 Holthoff HP, Li Z, Fassbender J. et al. Cyclic peptides for effective treatment in a long-term model of Graves disease and orbitopathy in female mice. Endocrinology 2017; 158: 2376-2390
• 61 Fassbender J, Holthoff HP, Li ZM. et al. Therapeutic effects of short cyclic and combined epitope peptides in a long-term model of Graves' disease and orbitopathy. Thyroid 2019; 29: 258-267
• 62 Diana T, Ungerer M, Wuster C. et al. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model. J Autoimmun 2021; 122: 102666
• 63 Zhang M, Ding X, Wu LP. et al. A promising mouse model of Graves' orbitopathy induced by adenovirus expressing thyrotropin receptor A subunit. Thyroid 2021; 31: 638-648
• 64 Zhang M, Chong KKL, Chen Z-y. et al. Rapamycin improves Graves’ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. JCI Insight 2023; 8: e160377
• 65 Laukens D, Brinkman BM, Raes J. et al. Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiol Rev 2016; 40: 117-132
• 66 Moshkelgosha S, Masetti G, Berchner-Pfannschmidt U. et al. Gut microbiome in BALB/c and C57BL/6J mice undergoing experimental thyroid autoimmunity associate with differences in immunological responses and thyroid function. Horm Metab Res 2018; 50: 932-941
• 67 Ishaq HM, Mohammad IS, Shahzad M. et al. Molecular alteration analysis of human gut microbial composition in Graves' disease patients. Int J Biol Sci 2018; 14: 1558-1570
• 68 Shi TT, Xin Z, Hua L. et al. Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study. J Endocrinol Invest 2019; 42: 967-978
• 69 Shi TT, Xin Z, Hua L. et al. Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy. J Endocrinol Invest 2021; 44: 297-310
• 70 Su XH, Yin XL, Liu Y. et al. Gut dysbiosis contributes to the imbalance of Treg and Th17 Cells in Graves' disease patients by propionic acid. J Clin Endocrinol Metab 2020; 105
• 71 Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves orbitopathy vary with age and sex. Arch Ophthalmol 1993; 111: 197-201
• 72 Bartalena L, Piantanida E, Gallo D. et al. Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy. Front Endocrinol 2020; 11
• 73 Schluter A, Flogel U, Diaz-Cano S. et al. Graves' orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model. Sci Rep 2018; 8: 13096
• 74 Philipp S, Horstmann M, Hose M. et al. An early wave of macrophage infiltration intertwined with antigen-specific proinflammatory T cells and browning of adipose tissue characterizes the onset of orbital inflammation in a mouse model of Graves' orbitopathy. Thyroid 2022; 32: 283-293
• 75 Plohn S, Hose M, Schluter A. et al. Fingolimod improves the outcome of experimental Graves' disease and associated orbitopathy by modulating the autoimmune response to the thyroid-stimulating hormone receptor. Thyroid 2019; 29: 1286-1301